Dog Drug Heaven high in the hills above Edinburgh

With every new shiny or sparkly category coming through oncology pipelines, there’s nearly always a sense of fervent tulip mania once the niche reaches a certain threshold of new compounds moving into the clinic.

The latest such example is antibody-drug conjugates (ADCs).

It’s time to think about some of the practicalities and reality checks because few things in oncology R&D ought to be viewed from the perspective of rose tinted glasses.

Instead of breathless hype, we’re taking a common sense perspective deeply rooted in first principles around targeted therapies.

Look before you leap into the unknown – because there are plenty of clues regarding where this niche is headed for many early stage agents…

To learn more from our latest oncology conference coverage and get a heads up on key cancer research insights, subscribers can log-in or you can click to gain access to BSB Premium Content.

This content is restricted to subscribers

Posted by